Biosimilar Reimbursement Under The Sequester: The Lower The Price, The Bigger The Spread
This article was originally published in RPM Report
Executive Summary
Novartis has become the first company to announce a biosimilar application in the US, and will likely become the first company to test the Medicare reimbursement formula for the new product class. The 2% sequester cut in Medicare may actually make that formula more attractive for biosimilars than the original law. Here’s how.
You may also be interested in...
Reimbursement of Biosimilar and Biosimilar-similar ESAs
Affymax received FDA approval for the first new ESA in years. Now the company is trying to secure favorable reimbursement for its product, Omontys. The case raises the question of how CMS will treat biosimilar ESAs.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.